Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01503
|
|||||
| Drug Name |
Cepharanthine
|
|||||
| Synonyms |
CEPHARANTHINE; Cepharanthin; (+)-Cepharanthine; O-Methylcepharanoline; Cepharantin; Cepharanthine [JAN]; UNII-7592YJ0J6T; CCRIS 6539; NSC 623442; BRN 0075231; 6',12'-Dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))oxyacanthan; CHEBI:3546; 7592YJ0J6T; NSC623442; Cepharanthine (JAN); NSC-623442; ecaene (non-preferred name); DSSTox_RID_81253; DSSTox_CID_25957; DSSTox_GSID_45957; Oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))-; CAS-481-49-2; SR-01000779734; Cepharanthin,(S)
|
|||||
| Indication | Thrombocytopenia [ICD11: 3B64] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C37H38N2O6
|
|||||
| Canonical SMILES |
CN1CCC2=CC3=C(C4=C2C1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)CC7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3
|
|||||
| InChI |
InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29+/m1/s1
|
|||||
| InChIKey |
YVPXVXANRNDGTA-WDYNHAJCSA-N
|
|||||
| CAS Number |
CAS 481-49-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 606.7 | Topological Polar Surface Area | 61.9 | ||
| Heavy Atom Count | 45 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
6.5
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:3546
|
|||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | The Drugs.com International Drug Name Database: cepharanthine | |||||
| 2 | Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein. J Pharmacol Exp Ther. 1995 Oct;275(1):73-8. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.